Michael Burry of Scion Asset Management Sees Regeneron Pharmaceuticals Regenerate. Should You Buy In Too?
Michael Burry of The Big Short fame just made Regeneron his second-largest bet. Institutions agree. Is this biotech giant ready to regenerate portfolios?
Finance of America Companies (FOA): When Leon Cooperman Bets, Do You Fetch?
Leon Cooperman doubled down on Finance of America (FOA), betting big on its reverse mortgage growth story. Profits are back, institutions are circling, and the stock trades at just 3.7x earnings. Is this the start of a Rocky-style comeback — or another value trap waiting to snap shut?
Biotech Hedge Fund Extraordinaire Baker Bros. Advisors LP Adds To Its Stake in Madrigal Pharmaceuticals (MDGL): Should You Buy?
When the Baker Bros. — biotech’s most famous hedge fund — start scooping up more shares of Madrigal Pharma (MDGL), you know something’s cooking. With Rezdiffra sales booming, losses shrinking, and Wall Street titans circling, the tune of this Madrigal might be worth humming 🎶.
Rapid7 (RPD): Slow Growth, But Jana Sees Value & Institutions Are All In
Rapid7 (RPD) just caught hedge fund JANA Partners’ eye with a $15M insider buy. Institutions are piling in, but growth remains slow. Is this a value gem in cybersecurity or just another trap? We break it down with humor, icons, and insights.
Bill Ackman’s Pershing Square Still Noshes on Restaurant Brands International (QSR). Should You?
Restaurant Brands International ($QSR) is cooking up dividends, international growth, and a massive Burger King reset. Bill Ackman’s Pershing Square still owns a super-sized stake—should you follow suit, or wait for a dip before ordering?
Bill Ackman’s Pershing Square Still Hearts Brookfield (BN)
Bill Ackman still loves Brookfield, his top Pershing Square bet—now up 39%! But at nearly $68 per share, has the value vanished? We dig into insider buying, institutional interest, financial highlights, and whether this former bargain is still a buy. 💼📈
Cathie Wood’s Ark Bought More Teradyne (TER)… Should You?
Cathie Wood is doubling down on Teradyne, a robotics and semiconductor test powerhouse with a $1B buyback plan and big AI dreams. Should investors follow? Our fun, fact-filled breakdown has you covered.
Paul Tudor Jones Loves IWM. Should You?
Paul Tudor Jones is going heavy on small caps—and maybe prepping for AI-induced doom. With 1,350+ positions and an options playbook that could fill a library, what’s his real bet? And more importantly: should you follow? Read on, but don’t YOLO.
GAMCO Investors Is Full of Winners — Except Paramount (PARA): Why This One Dud Might Finally Shine
Is Paramount Global a value trap—or a future media giant in disguise? Streaming growth, big-name backers like GAMCO and Vanguard, and Apple buyout rumors make this drama worth watching. 🍿🎥
ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?
Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?